Category: MassDevice Q&A
AccuVein CEO Ron Goldman tells MassDevice about his firm's hand-held vascular imaging technology.
Venipuncture – drawing blood or establishing an intravenous feed – is the most common invasive medical procedure. For many patients, it's a painful exercise in frustration when clinicians struggle to find a blood vessel, sometimes requiring multiple needle sticks.
AccuVein and CEO Ron Goldman aim to change all that with the company's AV300 vascular illumination device. The wireless, handheld module uses a pair of lasers to paint a patient's arm with light, making otherwise invisible or hard-to-find blood vessels apparent to the naked eye.
Stu Randle, CEO of GI Dynamics, discusses the company's recent Australian IPO in an interview with MassDevice.
GI Dynamics (ASX:GID) has been the talk of the medical device industry lately.
Mela Sciences CEO Joseph Gulfo tells MassDevice about the path from nearly assured clearance in June 2009 to the brink of clearance more than two years later.
Click to play
Former Medtronic CEO Bill Hawkins, in an exclusive interview with MassDevice.com, tells us about the one that got away: Guidant Corp.'s stent-making operation.
There's no shortage of ink spilled over the feeding frenzy over Guidant Corp., which ended in Boston Scientific Corp.'s (NYSE:BSX) ill-fated $26 billion acquisition in 2006. But there's one nugget from the spectacle that hasn't received much attention.
Seasoned patent attorney David Dykeman takes us through the America Invents Act in a podcast interview highlighting the challenges and opportunities the reform bill poses for the medical device industry.
This week President Barack Obama is expected to sign a patent reform bill marking the most dramatic changes to the patent system in decades, drawing adulation and ire from varying sectors of the innovation economy.
The American Invents Act, six years in the making, contains several sweeping changes, but the main bone of contention is a transformation of the U.S. patent system from a first-to-invent application process to a first-to-file process.
Boston Scientific makes a generational move in choosing Johnson & Johnson executive Michael Mahoney, but who is the 46-year-old medical device veteran?
In naming Michael Mahoney as the heir apparent to J. Raymond Elliott, Boston Scientific Corp. (NYSE:BSX) fired another salvo in a long-running blood feud with Johnson & Johnson Corp. (NYSE:JNJ).
Neuronetics president & CEO Bruce Shook on treating an incurable psychiatric disorder, chasing reimbursement and turning psychiatrists into medical device proceduralists.
Neuronetics' NeuroStar TMS therapy system
Neuronetics Inc. is paving the way for a new type of depression therapy, a non-invasive electromagnetic field treatment designed to stimulate brain cells linked to depression.
Bruce Shook, co-founder, president & CEO, talked to MassDevice about pioneering the market for the only FDA-cleared transcranial magnetic stimulation system to date, his company's NeuroStar TMS system.
The therapy, which won the FDA nod in 2008, is a rarity in the med-tech world: A device-based approach to a psychiatric disorder.